EcoDrugPlus

Platelet Activating Factor Receptor

Ensembl ID : ENSOMEG00000015205
Gene Symbol: PTAFR
3 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSOMEG00000015665
Gene Symbol: PDGFRA
3 Cross references
203 Possible Orthologues:

Platelet-Derived Growth Factor Receptor Beta-Like

Ensembl ID : ENSOMEG00000004646
Gene Symbol: LOC112153320
3 Cross references
198 Possible Orthologues:

Polo Like Kinase 1

Ensembl ID : ENSOMEG00000019980
Gene Symbol: PLK1
4 Cross references
188 Possible Orthologues:

Polo Like Kinase 4

Ensembl ID : ENSOMEG00000005801
Gene Symbol: PLK4
3 Cross references
215 Possible Orthologues:

Poly (Adp-Ribose) Polymerase 2

Ensembl ID : ENSOMEG00000022765
Gene Symbol: PARP2
1 Cross references
185 Possible Orthologues:

Poly(Adp-Ribose) Polymerase Family Member 3

Ensembl ID : ENSOMEG00000013854
Gene Symbol: PARP3
3 Cross references
197 Possible Orthologues:

Porcupine O-Acyltransferase

Ensembl ID : ENSOMEG00000003518
Gene Symbol: PORCN
3 Cross references
193 Possible Orthologues:

Potassium Channel, Subfamily K, Member 9

Ensembl ID : ENSOMEG00000011413
Gene Symbol: KCNK9
1 Cross references
218 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 11

Ensembl ID : ENSOMEG00000023565
Gene Symbol: KCNJ11
3 Cross references
188 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSOMEG00000008120
Gene Symbol: KCNJ2
3 Cross references
202 Possible Orthologues:

Potassium Inwardly Rectifying Channel Subfamily J Member 2

Ensembl ID : ENSOMEG00000021077
Gene Symbol: KCNJ2
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).